NASDAQ:BIIB

Biogen - BIIB Stock Forecast, Price & News

$267.00

+2.72 (+1.03%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $257.02
▼
$271.49
50-Day Range: $194.69
▼
$276.61
52-Week Range: $187.16
▼
$290.76

Volume: 3.75 million shs
Average Volume: 1.26 million shs
Market Capitalization: $38.75 billion

P/E Ratio: 19.04
Dividend Yield: N/A
Price Target: $268.70

Biogen MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.62 Rating Score
Upside/Downside: 1.6% Upside
$271.26 Price Target
Short Interest: Healthy
1.43% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.56
Upright™ Environmental Score
News Sentiment: 0.66
Based on 74 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -4.01%
From $16.44 to $15.78 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

591st out of 1,093 stocks

Biological Products, Except Diagnostic Industry

100th out of 171 stocks

2.3

Analyst's Opinion

Consensus Rating
Biogen has received a consensus rating of Buy. The company's average rating score is 2.62, and is based on 16 buy ratings, 10 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $271.26, Biogen has a forecasted upside of 1.6% from its current price of $267.00.
Amount of Analyst Coverage
Biogen has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.43% of the float of Biogen has been sold short.
Short Interest Ratio / Days to Cover
Biogen has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biogen has recently increased by 9.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biogen does not currently pay a dividend.
Dividend Growth
Biogen does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Biogen has received a 50.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Dimethyl fumarate ", "Natalizumab", "Rituximab", and "Neuromuscular disorders medication" products. See details.
Environmental Sustainability
The Environmental Impact score for Biogen is -2.56.

3.1

News and Social Media Coverage

News Sentiment
Biogen has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 74 news articles for Biogen this week, compared to 14 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 10 reddit mentions for Biogen this week, compared to 2 mentions on an average week.
Search Interest
33 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 154% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biogen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.65% of the stock of Biogen is held by insiders.
Percentage Held by Institutions
83.45% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Biogen are expected to decrease by -4.01% in the coming year, from $16.44 to $15.78 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biogen is 19.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.48.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biogen is 19.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 122.13.
Price to Earnings Growth Ratio
Biogen has a PEG Ratio of 1.68. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Biogen has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Biogen (NASDAQ:BIIB) Stock

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

September 30, 2022 | fool.com

Why Biogen Stock Popped as Much as 37.1% This Week - The Motley Fool

September 30, 2022 | finance.yahoo.com

Why Biogen Stock Popped as Much as 37.1% This Week

September 30, 2022 | CRE Income Fund (Ad)

How To Earn a Tax-Advantaged 10% Dividend Yield

The average annual return of commercial real estate over 20 years is roughly 9.5%, nearly 1% greater than the S&P 500's average annual return of 8.6%. The CRE Income Fund pays an annual 10% dividend yield and is a long-term strategy that returns over $25,000 for every $10,000 invested over the next ten years.

September 30, 2022 | investors.com

Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review | Investor's Business Daily - Investor's Business Daily

September 30, 2022 | benzinga.com

Here's How Much $100 Invested In Biogen 20 Years Ago Would Be Worth Today - Biogen (NASDAQ:BIIB) - Benzinga

September 30, 2022 | bloomberg.com

Biogen Adds $10 Billion in Value as Alzheimer's Win Lifts Peers - Bloomberg

September 30, 2022 | globenewswire.com

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab) - GlobeNewswire

September 30, 2022 | finance.yahoo.com

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)

September 30, 2022 | CRE Income Fund (Ad)

How To Earn a Tax-Advantaged 10% Dividend Yield

September 30, 2022 | americanbankingnews.com

Royal Bank of Canada Increases Biogen (NASDAQ:BIIB) Price Target to $321.00

September 30, 2022 | americanbankingnews.com

Biogen (NASDAQ:BIIB) PT Raised to $280.00 at Piper Sandler

September 30, 2022 | americanbankingnews.com

Wells Fargo & Company Boosts Biogen (NASDAQ:BIIB) Price Target to $350.00

September 30, 2022 | americanbankingnews.com

Biogen (NASDAQ:BIIB) Lifted to "Outperform" at BMO Capital Markets

September 29, 2022 | nasdaq.com

BIIB Crosses Above Average Analyst Target

September 29, 2022 | bizjournals.com

Five questions around Biogen in wake of the new Alzheimer's drug data

September 29, 2022 | msn.com

Biogen Stock Clings to Key Level After Explosive Rally

September 29, 2022 | nasdaq.com

Is Biogen a Smart Biotech Stock to Buy Right Now?

September 29, 2022 | finance.yahoo.com

Are Investors Undervaluing Biogen Inc. (NASDAQ:BIIB) By 40%?

September 29, 2022 | finance.yahoo.com

LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

September 29, 2022 | washingtonpost.com

Analysis | New Alzheimer's Drug From Biogen and Eisai Is Just the Beginning - The Washington Post

September 29, 2022 | americanbankingnews.com

Biogen (NASDAQ:BIIB) Upgraded to "Buy" by Mizuho

September 29, 2022 | americanbankingnews.com

Brokerages Set Biogen Inc. (NASDAQ:BIIB) Target Price at $256.15

September 29, 2022 | benzinga.com

What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer's Data - Biogen (NASDAQ:BIIB) - Benzinga

September 29, 2022 | ft.com

Biogen and Eisai shares surge after Alzheimer's drug trial success - Financial Times

September 28, 2022 | benzinga.com

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

September 28, 2022 | businessinsider.com

Biogen's New Alzheimer's Drug Is a Big Win for Itself — and Its Rivals - Business Insider

September 28, 2022 | cnbc.com

Stocks making the biggest moves premarket: Biogen, Thor Industries, Lyft and more - CNBC

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings: 7/20/2022
Today: 9/30/2022
Next Earnings (Estimated): 10/19/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:BIIB
CUSIP: 09062X10
CIK: 875045
Web: www.biogen.com
Phone: (617) 679-2000
Fax: 617-679-2617
Employees: 9,610
Year Founded: 1978

Price Target and Rating

Average Stock Price Forecast: $271.26
High Stock Price Forecast: $360.00
Low Stock Price Forecast: $190.00
Forecasted Upside/Downside: +0.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.62
Research Coverage: 26 Analysts

Profitability

EPS (Most Recent Fiscal Year): $14.02
Trailing P/E Ratio: 19.04
Forward P/E Ratio: 16.24
P/E Growth: 1.68
Net Income: $1.56 billion
Net Margins: 19.36%
Pretax Margin: 21.75%
Return on Equity: 22.36%
Return on Assets: 10.42%

Debt

Debt-to-Equity Ratio: 0.53
Current Ratio: 1.94
Quick Ratio: 1.68

Sales & Book Value

Annual Sales: $10.98 billion
Price / Sales: 3.53
Cash Flow: $26.23 per share
Price / Cash Flow: 10.18
Book Value: $74.61 per share
Price / Book: 3.58

Miscellaneous

Outstanding Shares: 145,113,000
Free Float: 144,170,000
Market Cap: $38.75 billion
Optionable: Optionable
Beta: 0.43

Social Links

Key Executives

Mr. Michel Vounatsos (Age 60)
CEO & Director
Comp: $3.11M

Mr. Michael R. McDonnell CPA (Age 58)
Exec. VP & CFO
Comp: $1.86M

Ms. Susan H. Alexander Esq. (Age 65)
Exec. VP, Chief Legal Officer & Sec.
Comp: $1.79M

Ms. Robin C. Kramer (Age 56)
Sr. VP & Chief Accounting Officer

Ms. Nicole Murphy
Head of Pharmaceutical Operations & Technology

Mr. Michael Hencke
Head of Investor Relations

Ms. Natacha Gassenbach
Chief Communication Officer & Head of Corp. Affairs

Dr. Ginger Gregory (Age 54)
Exec. VP & Chief HR Officer

Dr. Anabella Villalobos Ph.D.
Head of Biotherapeutics & Medicinal Sciences

Dr. Sanjay Jariwala
Sr. VP of Worldwide Medical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?: 26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 10 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.
What is Biogen's stock price forecast for 2022?: 26 Wall Street research analysts have issued twelve-month price targets for Biogen's shares. Their BIIB share price forecasts range from $190.00 to $360.00. On average, they expect the company's share price to reach $271.26 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.
How have BIIB shares performed in 2022?: Biogen's stock was trading at $239.92 on January 1st, 2022. Since then, BIIB shares have increased by 11.3% and is now trading at $267.00.
View the best growth stocks for 2022 here.
When is Biogen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 19th 2022.
View our BIIB earnings forecast.
How were Biogen's earnings last quarter?: Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings results on Wednesday, July, 20th. The biotechnology company reported $5.25 earnings per share for the quarter, beating analysts' consensus estimates of $4.09 by $1.16. The biotechnology company earned $2.59 billion during the quarter, compared to the consensus estimate of $2.48 billion. Biogen had a trailing twelve-month return on equity of 22.36% and a net margin of 19.36%. The business's revenue for the quarter was down 6.7% on a year-over-year basis. During the same period last year, the company earned $5.68 earnings per share.
Read the conference call transcript.
What guidance has Biogen issued on next quarter's earnings?: Biogen issued an update on its FY 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share (EPS) guidance of $15.25-$16.75 for the period, compared to the consensus earnings per share estimate of $15.54. The company issued revenue guidance of $9.90 billion-$10.10 billion, compared to the consensus revenue estimate of $9.84 billion.

What is Michel Vounatsos' approval rating as Biogen's CEO?: 394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.
What other stocks do shareholders of Biogen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).
What is Biogen's stock symbol?: Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How do I buy shares of Biogen?: Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biogen's stock price today?: One share of BIIB stock can currently be purchased for approximately $267.00.
How much money does Biogen make?: Biogen (NASDAQ:BIIB) has a market capitalization of $38.75 billion and generates $10.98 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $14.02 on an earnings per share basis.
How many employees does Biogen have?: The company employs 9,610 workers across the globe.
Does Biogen have any subsidiaries?: The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?: Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 9/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biogen - BIIB Stock Forecast, Price & News

Biogen MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Social Mentions This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biogen (NASDAQ:BIIB) Stock

BIIB Stock News Headlines

BIIB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BIIB Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™